S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
NASDAQ:QNRX

Quoin Pharmaceuticals - QNRX Stock Forecast, Price & News

$4.91
-0.57 (-10.40%)
(As of 08/18/2022 05:45 PM ET)
Add
Compare
Today's Range
$4.71
$5.33
50-Day Range
$3.85
$19.80
52-Week Range
$3.58
$444.00
Volume
2.57 million shs
Average Volume
749,288 shs
Market Capitalization
$3.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.00

Quoin Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
918.3% Upside
$50.00 Price Target
Short Interest
Healthy
9.30% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.28mentions of Quoin Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.50) to ($5.25) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

QNRX stock logo

About Quoin Pharmaceuticals (NASDAQ:QNRX) Stock

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.

Quoin Pharmaceuticals Price Performance

Shares of Quoin Pharmaceuticals stock opened at $5.48 on Thursday. The business has a fifty day simple moving average of $5.84 and a two-hundred day simple moving average of $10.99. Quoin Pharmaceuticals has a 12 month low of $3.58 and a 12 month high of $444.00.

Quoin Pharmaceuticals (NASDAQ:QNRX - Get Rating) last announced its quarterly earnings data on Monday, May 23rd. The company reported ($2.50) EPS for the quarter. On average, sell-side analysts anticipate that Quoin Pharmaceuticals will post -6.5 earnings per share for the current year.

Analyst Upgrades and Downgrades

QNRX has been the subject of a number of research analyst reports. LADENBURG THALM/SH SH initiated coverage on Quoin Pharmaceuticals in a research note on Friday, May 6th. They issued a "buy" rating and a $25.00 price target for the company. Maxim Group dropped their price target on Quoin Pharmaceuticals to $25.00 in a research note on Thursday, May 26th.

Receive QNRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quoin Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

QNRX Stock News Headlines

Why Are Quoin Pharma Shares Trading Higher Today?
Why Quoin Pharmaceuticals Stock Is Trading Higher
See More Headlines
Receive QNRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quoin Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

QNRX Company Calendar

Last Earnings
5/23/2022
Today
8/18/2022
Next Earnings (Confirmed)
8/18/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:QNRX
Employees
2
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$50.00
High Stock Price Forecast
$100.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+918.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-21,460,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.98 per share

Miscellaneous

Free Float
N/A
Market Cap
$3.94 million
Optionable
Not Optionable
Beta
1.63

Key Executives

  • Dr. Michael Myers Ph.D. (Age 60)
    Co-Founder, CEO & Chairman
    Comp: $1.03M
  • Ms. Denise Carter (Age 53)
    Co-Founder, COO & Director
    Comp: $846k
  • Mr. Gordon Bruce Dunn J.D. (Age 58)
    Chief Financial Officer
    Comp: $417k













QNRX Stock - Frequently Asked Questions

Should I buy or sell Quoin Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quoin Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" QNRX shares.
View QNRX analyst ratings
or view top-rated stocks.

What is Quoin Pharmaceuticals' stock price forecast for 2022?

3 Wall Street analysts have issued 1 year price targets for Quoin Pharmaceuticals' shares. Their QNRX share price forecasts range from $25.00 to $100.00. On average, they anticipate the company's share price to reach $50.00 in the next year. This suggests a possible upside of 812.4% from the stock's current price.
View analysts price targets for QNRX
or view top-rated stocks among Wall Street analysts.

How have QNRX shares performed in 2022?

Quoin Pharmaceuticals' stock was trading at $22.75 at the beginning of the year. Since then, QNRX shares have decreased by 75.9% and is now trading at $5.48.
View the best growth stocks for 2022 here
.

When is Quoin Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 18th 2022.
View our QNRX earnings forecast
.

How were Quoin Pharmaceuticals' earnings last quarter?

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) released its quarterly earnings data on Monday, May, 23rd. The company reported ($2.50) EPS for the quarter.

When did Quoin Pharmaceuticals' stock split?

Quoin Pharmaceuticals shares reverse split before market open on Monday, August 1st 2022. The 1-12.5 reverse split was announced on Monday, August 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is Quoin Pharmaceuticals' stock symbol?

Quoin Pharmaceuticals trades on the NASDAQ under the ticker symbol "QNRX."

Who are Quoin Pharmaceuticals' major shareholders?

Quoin Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (8.09%).

How do I buy shares of Quoin Pharmaceuticals?

Shares of QNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Quoin Pharmaceuticals' stock price today?

One share of QNRX stock can currently be purchased for approximately $5.48.

How much money does Quoin Pharmaceuticals make?

Quoin Pharmaceuticals (NASDAQ:QNRX) has a market capitalization of $4.38 million.

How can I contact Quoin Pharmaceuticals?

Quoin Pharmaceuticals' mailing address is 23 HATA`AS STREET, KFAR SABA L3, 44425. The official website for the company is cellect.co. The company can be reached via phone at 972-9974-1444, via email at ir@cellectbio.com, or via fax at 972-9767-8750.

This page (NASDAQ:QNRX) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.